Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508910 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
A Phase 3 study, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT01508910 is a Phase 3 study that has completed, run by Lisata Therapeutics. The registered enrollment target is 291 participants.
The verdict
NCT01508910, a Phase 3 study, has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
Interventions
- OTHER Standard of care
- BIOLOGICAL Auto-CD34+ cells
- BIOLOGICAL Placebo: Diluent used to suspend Auto-CD34+ cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508910
The ClinicalTrials.gov registry entry for NCT01508910 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of care is the first listed.
NCT01508910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508910 about?
NCT01508910 is a clinical study titled "Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina". The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
What is the current status of trial NCT01508910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2012-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01508910?
The interventions under investigation include: Standard of care (OTHER), Auto-CD34+ cells (BIOLOGICAL), Placebo: Diluent used to suspend Auto-CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01508910?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.